The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Strategy for detection of prostate cancer based on relation between prostate specific antigen at age 40-55 and long term risk of metastasis: case-control study
Open accessAbstract
OBJECTIVE: To determine the association between concentration of prostate specific antigen (PSA) at age 40-55 and subsequent risk of prostate cancer metastasis and mortality in an unscreened population to evaluate when to start screening for prostate cancer and whether rescreening could be risk stratified. DESIGN: Case-control study with 1:3 matching nested within a highly representative population based cohort study. SETTING: Malmö Preventive Project, Sweden. PARTICIPANTS: 21,277 Swedish men aged 27-52 (74% of the eligible population) who provided blood at baseline in 1974-84, and 4922 men invited to provide a second sample six years later. Rates of PSA testing remained extremely low during median follow-up of 27 years. MAIN OUTCOME MEASURES: Metastasis or death from prostate cancer ascertained by review of case notes. RESULTS: Risk of death from prostate cancer was associated with baseline PSA: 44% (95% confidence interval 34% to 53%) of deaths occurred in men with a PSA concentration in the highest 10th of the distribution of concentrations at age 45-49 (≥ 1.6 µg/L), with a similar proportion for the highest 10th at age 51-55 (≥ 2.4 µg/L: 44%, 32% to 56%). Although a 25-30 year risk of prostate cancer metastasis could not be ruled out by concentrations below the median at age 45-49 (0.68 µg/L) or 51-55 (0.85 µg/L), the 15 year risk remained low at 0.09% (0.03% to 0.23%) at age 45-49 and 0.28% (0.11% to 0.66%) at age 51-55, suggesting that longer intervals between screening would be appropriate in this group. CONCLUSION: Measurement of PSA concentration in early midlife can identify a small group of men at increased risk of prostate cancer metastasis several decades later. Careful surveillance is warranted in these men. Given existing data on the risk of death by PSA concentration at age 60, these results suggest that three lifetime PSA tests (mid to late 40s, early 50s, and 60) are probably sufficient for at least half of men.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Multiple Imputation for Nonresponse in Surveys
Rubin, D. B. (1987) · Wiley Series in Probability and Statistics · doi:10.1002/9780470316696 · Cited by 20,701
Prostate-Cancer Mortality at 11 Years of Follow-up
Schröder, F. H., Hugosson, J., Roobol, M. J., Tammela, T. L. J., Ciatto, S., Nelen, V., Kwiatkowski, M., Lujan, M., Lilja, H., Zappa, M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113135 · Cited by 1,245
Self-citationThe completeness of the Swedish Cancer Register – a sample survey for year 1998
Barlow, L., Westergren, K., Holmberg, L., & Talbäck, M. (2009) · Acta Oncologica · doi:10.1080/02841860802247664 · Cited by 1,236
Longitudinal Evaluation of Prostate-Specific Antigen Levels in Men With and Without Prostate Disease
Carter, H. B. (1992) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1992.03480160073037 · Cited by 1,096
Clinical risk factors, DNA variants, and the development of type 2 diabetes
Lyssenko, V., Jonsson, A., Almgren, P., Pulizzi, N., Isomaa, B., Tuomi, T., Berglund, G., Altshuler, D., Nilsson, P., & Groop, L. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801869 · Cited by 938
Self-citationMortality results from the Göteborg randomised population-based prostate-cancer screening trial
Hugosson, J., Carlsson, S., Aus, G., Bergdahl, S., Khatami, A., Lodding, P., Pihl, C.-G., Stranne, J., Holmberg, E., & Lilja, H. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70146-7 · Cited by 936
Self-citationGermline Mutations in HOXB13 and Prostate-Cancer Risk
Ewing, C. M., Ray, A. M., Lange, E. M., Zuhlke, K. A., Robbins, C. M., Tembe, W. D., Wiley, K. E., Isaacs, S. D., Johng, D., Wang, Y., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1110000 · Cited by 658
Vickers, A. J., Cronin, A. M., Bjork, T., Manjer, J., Nilsson, P. M., Dahlin, A., Bjartell, A., Scardino, P. T., Ulmert, D., & Lilja, H. (2010) · BMJ · doi:10.1136/bmj.c4521 · Cited by 243
Self-citationLin, D. W., Newcomb, L. F., Brown, E. C., Brooks, J. D., Carroll, P. R., Feng, Z., Gleave, M. E., Lance, R. S., Sanda, M. G., Thompson, I. M., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3283 · Cited by 139
Prostate-Specific Antigen as Predictor of Prostate Cancer in Black Men and White Men
Whittemore, A. S., Lele, C., FRIEDMAN, G. D., Stamey, T. A., Vogelman∥, J. H., & Orentreich∥, N. (1995) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/87.5.354 · Cited by 99
Ulmert, D., Becker, C., Nilsson, J., Piironen, T., Björk, T., Hugosson, J., Berglund, G. L., & Lilja, H. G. (2005) · Clinical Chemistry · doi:10.1373/clinchem.2005.050641 · Cited by 66
Self-citationSandblom, G., Dufmats, M., Olsson, M., & Varenhorst, E. (2003) · Scandinavian Journal of Urology and Nephrology · doi:10.1080/00365590310008839 · Cited by 47
Ørsted, D. D., Nordestgaard, B. G., Jensen, G. B., Schnohr, P., & Bojesen, S. E. (2011) · European Urology · doi:10.1016/j.eururo.2011.11.007 · Cited by 46
Balancing the harms and benefits of early detection of prostate cancer
van Leeuwen, P. J., Connolly, D., Tammela, T. L. J., Auvinen, A. P., Ries Kranse, C., Roobol, M. J., Schröder, F. H., & Gavin, A. (2010) · Cancer · doi:10.1002/cncr.25474 · Cited by 44
Elevated Prostate-Specific Antigen Levels Up to 25 Years Prior to Death from Prostate Cancer
Kuller, L. H., Thomas, A. J., Grandits, G. A., & Neaton, J. D. (2004) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.373.13.3 · Cited by 29
Ørsted, D. D., Nordestgaard, B. G., & Bojesen, S. E. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.30.5_suppl.5 · Cited by 4
Cited by
Mottet, N., Bellmunt, J., Bolla, M., Briers, E., Cumberbatch, M. G., De Santis, M., Fossati, N., Gross, T., Henry, A. M., Joniau, S., et al. (2017) · European Urology · doi:10.1016/j.eururo.2016.08.003 · Cited by 3,227
Mottet, N., van den Bergh, R. C. N., Briers, E., Van den Broeck, T., Cumberbatch, M. G., De Santis, M., Fanti, S., Fossati, N., Gandaglia, G., Gillessen, S., et al. (2021) · European Urology · doi:10.1016/j.eururo.2020.09.042 · Cited by 2,802
Heidenreich, A., Bastian, P. J., Bellmunt, J., Bolla, M., Joniau, S., van der Kwast, T., Mason, M., Matveev, V., Wiegel, T., Zattoni, F., et al. (2014) · European Urology · doi:10.1016/j.eururo.2013.09.046 · Cited by 1,936
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,609
Schröder, F. H., Hugosson, J., Roobol, M. J., Tammela, T. L. J., Zappa, M., Nelen, V., Kwiatkowski, M., Lujan, M., Määttänen, L., Lilja, H., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60525-0 · Cited by 1,566
Self-citation
Metadata
- Authors
- Vickers, A. J., Ulmert, D., Sjoberg, D. D., Bennette, C. J., Bjork, T., Gerdtsson, A., Manjer, J., Nilsson, P. M., Dahlin, A., Bjartell, A., Scardino, P. T., & Lilja, H.
- Venue
- BMJ
- Publisher
- BMJ
- Published
- 2013-04-16
- Volume
- 346
- Issue
- apr15 5
- Pages
- f2023-f2023
- ISSN
- 1756-1833 (ISSN-L)
- OpenAlex
- W2145062298
- Cited by
- 282
- References
- 16
- FWCI
- 27.04
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.